ESC 2021 FIDELITY was a prespecified pooled analysis of FIDELIO-DKD and FIGARO-DKD, which showed that finerenone reduced the risk of CV and renal outcomes in patients with T2DM and mild-to-severe CKD.
This study showed that estimated age-standardized prevalence of diabetes among US adults increased significantly from 9.8% in 1999-2000 to 14.3% in 2017-2018. In 2015-2018, only 21.2% of adults with diagnosed diabetes achieved individualized HbA1C targets, BP <130/80 mmHg, and LDL-c <100 mg/dL.
Microvascular disease (MVD) was associated with the development of HF in adults with T2DM, independently of traditional risk factors including CAD.
ESC HF 2021 Use of empagliflozin was associated with reduced risk of CV and renal events, and all-cause mortality compared to use of DPP-4i in T2DM patients in a real world setting.
ACC 2021 Risk of new-onset AF was reduced by 29% in patients randomized to finerenone compared to placebo in a population of patients with T2DM and CKD.
ACC 2021 A pooled patient-level analysis showed that sotagliflozin significantly reduced total CV deaths, HF hospitalizations, and urgent visits for HF across the full range of baseline EF, including in patients with HFpEF.
In the FIGARO-DKD phase 3 trial, the nonsteroidal MRA finerenone reduced the primary endpoint, a composite of CV death and non-fatal CV events, compared to placebo in patients with CKD and T2DM.
Adverse pregnancy outcomes (APOs) are associated with future development of CVD. The statement from the American Heart Association gives recommendations for strategies to reduce the long-term CVD risk in women with APOs.
A post hoc analysis of the LEADER trial showed that a reduction in albuminuria was associated with fewer CV and renal outcomes in patients with T2DM. Frederik Persson presents the results of this analysis.
This study investigated the relative risk of more than 50 clinical risk factors and biomarkers with incident CHD in 4 age groups in women.
Triglycerides and remnant-c, but not LDL-c and HDL-c, were associated with MACE in a primary prevention cohort of high CV risk subjects with high prevalence of diabetes and obesity.
The recommendations in the 2019 ESC guidelines on management of diabetes and CVD have shifted from a glucose-centric approach towards an event-driven approach.